FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:429 January 25, 2007 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

Edited by Antonio Cano Sanchez, Joaquim Calaf i Alsina, and José-Luis Dueñas-Díez. 357 pp., illustrated. Berlin, Springer, 2006. $169. ISBN 978-3-540-24227-7.

In the mid-1980s, it was discovered that the nonsteroidal antiestrogens tamoxifen and raloxifene (then known as keoxifene) can switch on (estrogenic action) or switch off (antiestrogenic action) responses at estrogen target sites around the body. This finding evoked a conceptual change in pharmacology that opened the door to investigations of the clinical potential of drugs that are now called selective estrogen receptor modulators (SERMs) for the prevention of breast cancer, osteoporosis, and other diseases in women.

Twenty years later, the veteran SERM tamoxifen is still used to treat and prevent breast cancer (antiestrogenic action), but raloxifene, the failed breast cancer . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.